BioCryst Pharmaceuticals Inc
NASDAQ:BCRX
BioCryst Pharmaceuticals Inc
Revenue
BioCryst Pharmaceuticals Inc
Revenue Peer Comparison
Competitive Revenue Analysis
Latest Figures & CAGR of Competitors
Company | Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
BioCryst Pharmaceuticals Inc
NASDAQ:BCRX
|
Revenue
$331.4m
|
CAGR 3-Years
165%
|
CAGR 5-Years
74%
|
CAGR 10-Years
34%
|
|
Abbvie Inc
NYSE:ABBV
|
Revenue
$54.3B
|
CAGR 3-Years
6%
|
CAGR 5-Years
11%
|
CAGR 10-Years
11%
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Revenue
$27.1B
|
CAGR 3-Years
3%
|
CAGR 5-Years
4%
|
CAGR 10-Years
9%
|
|
Amgen Inc
NASDAQ:AMGN
|
Revenue
$28.2B
|
CAGR 3-Years
4%
|
CAGR 5-Years
3%
|
CAGR 10-Years
4%
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Revenue
$9.9B
|
CAGR 3-Years
17%
|
CAGR 5-Years
26%
|
CAGR 10-Years
23%
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Revenue
$13.1B
|
CAGR 3-Years
16%
|
CAGR 5-Years
14%
|
CAGR 10-Years
20%
|
BioCryst Pharmaceuticals Inc
Revenue Breakdown
Breakdown by Geography
BioCryst Pharmaceuticals Inc
Breakdown by Segments
BioCryst Pharmaceuticals Inc
Total Revenue:
331.4m
USD
|
Product:
324.7m
USD
|
Collaborative And Other Research And Development:
6.7m
USD
|
See Also
What is BioCryst Pharmaceuticals Inc's Revenue?
Revenue
331.4m
USD
Based on the financial report for Dec 31, 2023, BioCryst Pharmaceuticals Inc's Revenue amounts to 331.4m USD.
What is BioCryst Pharmaceuticals Inc's Revenue growth rate?
Revenue CAGR 10Y
34%
Over the last year, the Revenue growth was 22%. The average annual Revenue growth rates for BioCryst Pharmaceuticals Inc have been 165% over the past three years , 74% over the past five years , and 34% over the past ten years .